Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 2 8Phase 4 7Phase 1 7Phase 1/2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Imiquimod × Clear all
NCT02078648 2025-02-03

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Stemline Therapeutics, Inc.

Phase 1/2 Completed
74 enrolled 19 charts
CNS

Glioblastoma

NCT02224599 2020-04-24

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Kiromic BioPharma Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT00785122 2013-05-16

IMA910-101

Immatics Biotechnologies GmbH

Phase 1/2 Completed
92 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡